{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:26:09Z","timestamp":1792801569975,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Deputyship for Research and Innovation of the \u201cMinistry of Education\u201d in Saudi Arabia","award":["IFKSUDR_H150"],"award-info":[{"award-number":["IFKSUDR_H150"]}],"id":[{"id":"https:\/\/ror.org\/00q919b81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-024-00824-9","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T11:38:42Z","timestamp":1734521922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Potential cardioprotective effect of paroxetine against ventricular remodeling in an animal model of myocardial infarction: a comparative study"],"prefix":"10.1186","volume":"25","author":[{"given":"Asma S.","family":"Alonazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Almodawah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Aldigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anfal","family":"Bin Dayel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Alamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad R.","family":"Almotairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha F.","family":"El-Tohamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahani K.","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouf M.","family":"Alrasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"824_CR1","unstructured":"World Health Organization. Cardiovascular diseases. Accessed 14 Apr 2023."},{"issue":"7","key":"824_CR2","first-page":"e9349","volume":"12","author":"MA Khan","year":"2020","unstructured":"Khan MA, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020;12(7):e9349.","journal-title":"Cureus"},{"issue":"5","key":"824_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.repc.2020.05.002","volume":"39","author":"E Pereira","year":"2020","unstructured":"Pereira E, Pereira H. Socioeconomic impact of cardiovascular disease. Rev Port Cardiol (Engl Ed). 2020;39(5):253\u20134.","journal-title":"Rev Port Cardiol (Engl Ed)"},{"issue":"4","key":"824_CR4","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/cphy.c150006","volume":"5","author":"NG Frangogiannis","year":"2015","unstructured":"Frangogiannis NG. Pathophysiology of Myocardial Infarction. Compr Physiol. 2015;5(4):1841\u201375.","journal-title":"Compr Physiol"},{"key":"824_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/VHRM.S166157","volume":"15","author":"S Aydin","year":"2019","unstructured":"Aydin S, et al. Biomarkers in acute myocardial infarction: current perspectives. Vasc Health Risk Manag. 2019;15:1\u201310.","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"824_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11(5):255\u201365.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"824_CR7","doi-asserted-by":"publisher","first-page":"e027600","DOI":"10.1161\/JAHA.122.027600","volume":"12","author":"RYK Zhang","year":"2023","unstructured":"Zhang RYK, et al. Impact of Reperfusion on Temporal Immune Cell Dynamics After Myocardial Infarction. J Am Heart Assoc. 2023;12(4):e027600.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"824_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","volume":"119","author":"SD Prabhu","year":"2016","unstructured":"Prabhu SD, Frangogiannis NG. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ Res. 2016;119(1):91\u2013112.","journal-title":"Circ Res"},{"issue":"12","key":"824_CR9","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011;2(12):1097\u2013105.","journal-title":"Genes Cancer"},{"issue":"3","key":"824_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","volume":"35","author":"JN Cohn","year":"2000","unstructured":"Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling\u2013concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35(3):569\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"824_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1753-0407.12991","volume":"12","author":"S Lai","year":"2020","unstructured":"Lai S, et al. G protein-coupled receptor kinase-2: A potential biomarker for early diabetic cardiomyopathy. J Diabetes. 2020;12(3):247\u201358.","journal-title":"J Diabetes"},{"issue":"21","key":"824_CR12","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.4161\/cc.10.21.18042","volume":"10","author":"NT Vasudevan","year":"2011","unstructured":"Vasudevan NT, et al. Regulation of \u03b2-adrenergic receptor function: an emphasis on receptor resensitization. Cell Cycle. 2011;10(21):3684\u201391.","journal-title":"Cell Cycle"},{"issue":"3","key":"824_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/CIRCRESAHA.110.231233","volume":"109","author":"SL Belmonte","year":"2011","unstructured":"Belmonte SL, Blaxall BC. G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res. 2011;109(3):309\u201319.","journal-title":"Circ Res"},{"key":"824_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fphar.2019.00112","volume":"10","author":"C Murga","year":"2019","unstructured":"Murga C, et al. Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases. Front Pharmacol. 2019;10:112.","journal-title":"Front Pharmacol"},{"key":"824_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3389\/fphys.2013.00264","volume":"4","author":"A Cannavo","year":"2013","unstructured":"Cannavo A, Liccardo D, Koch WJ. Targeting cardiac \u03b2-adrenergic signaling via GRK2 inhibition for heart failure therapy. Front Physiol. 2013;4:264.","journal-title":"Front Physiol"},{"key":"824_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coemr.2020.09.004","volume":"16","author":"AC Arcones","year":"2021","unstructured":"Arcones AC, et al. G protein\u2013coupled receptor kinase 2 at crossroads of metabolic and cardiovascular diseases. Curr Opin Endocr Metabolic Res. 2021;16:75\u201385.","journal-title":"Curr Opin Endocr Metabolic Res"},{"issue":"17","key":"824_CR17","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/eurheartj\/ehi429","volume":"26","author":"G Iaccarino","year":"2005","unstructured":"Iaccarino G, et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J. 2005;26(17):1752\u20138.","journal-title":"Eur Heart J"},{"issue":"1","key":"824_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1527-3458.2001.tb00189.x","volume":"7","author":"M Bourin","year":"2001","unstructured":"Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev. 2001;7(1):25\u201347.","journal-title":"CNS Drug Rev"},{"issue":"11","key":"824_CR19","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1021\/cb3003013","volume":"7","author":"DM Thal","year":"2012","unstructured":"Thal DM, et al. Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol. 2012;7(11):1830\u20139.","journal-title":"ACS Chem Biol"},{"key":"824_CR20","doi-asserted-by":"crossref","unstructured":"Guo S, Carter R, Tilley D. Impact of paroxetine on proximal \u03b2-adrenergic receptor signaling. FASEB J. 2017;31(S1):992.3-992.3.","DOI":"10.1096\/fasebj.31.1_supplement.992.3"},{"issue":"277","key":"824_CR21","doi-asserted-by":"publisher","first-page":"277ra31","DOI":"10.1126\/scitranslmed.aaa0154","volume":"7","author":"SM Schumacher","year":"2015","unstructured":"Schumacher SM, et al. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Sci Transl Med. 2015;7(277):277ra31.","journal-title":"Sci Transl Med"},{"key":"824_CR22","doi-asserted-by":"publisher","first-page":"794584","DOI":"10.3389\/fcvm.2021.794584","volume":"8","author":"H Xu","year":"2021","unstructured":"Xu H, et al. Paroxetine and Mortality in Heart Failure: A Retrospective Cohort Study. Front Cardiovasc Med. 2021;8:794584.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"824_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S0006-3223(02)01394-X","volume":"52","author":"VK Yeragani","year":"2002","unstructured":"Yeragani VK, et al. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry. 2002;52(5):418\u201329.","journal-title":"Biol Psychiatry"},{"key":"824_CR24","doi-asserted-by":"crossref","unstructured":"Alonazi AS, et al. Cardioprotective effects of the GRK2 inhibitor paroxetine on isoproterenol-induced cardiac remodeling by modulating NF-\u03baB mediated prohypertrophic and profibrotic gene expression. Int J Mol Sci. 2023;24(24):17270.","DOI":"10.3390\/ijms242417270"},{"issue":"6","key":"824_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4070\/kcj.2019.0231","volume":"50","author":"H Won","year":"2020","unstructured":"Won H, et al. Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database. Korean Circ J. 2020;50(6):499\u2013508.","journal-title":"Korean Circ J"},{"issue":"9","key":"824_CR26","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/0022-2828(95)90013-6","volume":"27","author":"A Hanatani","year":"1995","unstructured":"Hanatani A, et al. Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. J Mol Cell Cardiol. 1995;27(9):1905\u201314.","journal-title":"J Mol Cell Cardiol"},{"key":"824_CR27","doi-asserted-by":"crossref","unstructured":"Azevedo PS, et al. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arq Bras Cardiol. 2016;106(1):62\u20139.","DOI":"10.5935\/abc.20160005"},{"issue":"3","key":"824_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.5935\/1678-9741.20110024","volume":"26","author":"HG Lobo Filho","year":"2011","unstructured":"Lobo Filho HG, et al. Experimental model of myocardial infarction induced by isoproterenol in rats. Rev Bras Cir Cardiovasc. 2011;26(3):469\u201376.","journal-title":"Rev Bras Cir Cardiovasc"},{"issue":"2","key":"824_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12012-015-9323-1","volume":"16","author":"K Mnafgui","year":"2016","unstructured":"Mnafgui K, et al. Protective Effect of Hydroxytyrosol Against Cardiac Remodeling After Isoproterenol-Induced Myocardial Infarction in Rat. Cardiovasc Toxicol. 2016;16(2):147\u201355.","journal-title":"Cardiovasc Toxicol"},{"issue":"1","key":"824_CR30","doi-asserted-by":"publisher","first-page":"e016364","DOI":"10.1161\/JAHA.120.016364","volume":"10","author":"X Sun","year":"2021","unstructured":"Sun X, et al. Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension. J Am Heart Association. 2021;10(1):e016364.","journal-title":"J Am Heart Association"},{"issue":"1","key":"824_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/jphp.13192","volume":"72","author":"W Qin","year":"2020","unstructured":"Qin W, et al. Metoprolol protects against myocardial infarction by inhibiting miR-1 expression in rats. J Pharm Pharmacol. 2020;72(1):76\u201383.","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"824_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/01.HYP.37.3.981","volume":"37","author":"FH Leenen","year":"2001","unstructured":"Leenen FH, Yuan B. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Hypertension. 2001;37(3):981\u20134.","journal-title":"Hypertension"},{"issue":"1","key":"824_CR33","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1038\/s41598-019-40847-5","volume":"9","author":"H Shi","year":"2019","unstructured":"Shi H, et al. The Effect of Electronic-Cigarette Vaping on Cardiac Function and Angiogenesis in Mice. Sci Rep. 2019;9(1):4085.","journal-title":"Sci Rep"},{"key":"824_CR34","first-page":"3714508","volume":"2019","author":"QW Wang","year":"2019","unstructured":"Wang QW, et al. Ginsenoside Re Improves Isoproterenol-Induced Myocardial Fibrosis and Heart Failure in Rats. Evid Based Complement Alternat Med. 2019;2019:3714508.","journal-title":"Evid Based Complement Alternat Med"},{"key":"824_CR35","doi-asserted-by":"crossref","unstructured":"Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979;582(1):67\u201378.","DOI":"10.1016\/0304-4165(79)90289-7"},{"issue":"1","key":"824_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jcp.29.1.73","volume":"29","author":"A Delides","year":"1976","unstructured":"Delides A, et al. An optimized semi-automatic rate method for serum glutathione reductase activity and its application to patients with malignant disease. J Clin Pathol. 1976;29(1):73\u20137.","journal-title":"J Clin Pathol"},{"issue":"2","key":"824_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","volume":"95","author":"H Ohkawa","year":"1979","unstructured":"Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351\u20138.","journal-title":"Anal Biochem"},{"issue":"14","key":"824_CR38","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1089\/ars.2014.5876","volume":"21","author":"ZM Huang","year":"2014","unstructured":"Huang ZM, et al. GRK2 in the heart: a GPCR kinase and beyond. Antioxid Redox Signal. 2014;21(14):2032\u201343.","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"824_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.21037\/atm.2020.02.93","volume":"8","author":"W Chen","year":"2020","unstructured":"Chen W, et al. Cardioprotection of cortistatin against isoproterenol-induced myocardial injury in rats. Ann Transl Med. 2020;8(6):309.","journal-title":"Ann Transl Med"},{"key":"824_CR40","doi-asserted-by":"crossref","unstructured":"Ahmed MI, et al. Cardioprotective effect of flibanserin against isoproterenol-induced myocardial infarction in female rats: role of cardiac 5-HT2A receptor gene\/5-HT\/Ca(2+) pathway. Pharmaceuticals (Basel). 2023;16(4):502.","DOI":"10.3390\/ph16040502"},{"key":"824_CR41","doi-asserted-by":"crossref","unstructured":"Cornelissen A, et al. Fibroblast growth factor 23 and outcome prediction in patients with acute myocardial infarction. J Clin Med. 2022;11(3):601.","DOI":"10.3390\/jcm11030601"},{"key":"824_CR42","doi-asserted-by":"crossref","unstructured":"St\u00f6hr R, et al. FGF23 in cardiovascular disease: innocent bystander or active mediator? Front Endocrinol. 2018;9:351.","DOI":"10.3389\/fendo.2018.00351"},{"key":"824_CR43","first-page":"100727","volume":"33","author":"IS Thorsen","year":"2021","unstructured":"Thorsen IS, et al. The relationship between Fibroblast Growth Factor 23 (FGF23) and cardiac MRI findings following primary PCI in patients with acute first time STEMI. Int J Cardiol Heart Vasc. 2021;33:100727.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"824_CR44","doi-asserted-by":"crossref","unstructured":"Tsai CK, et al. Low-dose propranolol prevents functional decline in catecholamine-induced acute heart failure in rats. Toxics. 2022;10(5):238.","DOI":"10.3390\/toxics10050238"},{"key":"824_CR45","doi-asserted-by":"crossref","unstructured":"B\u00f6ckmann I, et al. FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis. Int J Mol Sci. 2019;20(18):4634.","DOI":"10.3390\/ijms20184634"},{"key":"824_CR46","doi-asserted-by":"crossref","unstructured":"Meng Q, et al. MMI-0100 inhibits cardiac fibrosis in a mouse model overexpressing cardiac myosin binding protein C. J Am Heart Assoc. 2017;6(9):e006590.","DOI":"10.1161\/JAHA.117.006590"},{"issue":"2","key":"824_CR47","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199\u2013210.","journal-title":"J Pathol"},{"key":"824_CR48","doi-asserted-by":"crossref","unstructured":"Wang F, et al. Apigenin inhibits isoproterenol-induced myocardial fibrosis and Smad pathway in mice by regulating oxidative stress and miR-122-5p\/155-5p expressions. Drug Dev Res. 2022;83(4):1003\u20131015.","DOI":"10.1002\/ddr.21928"},{"issue":"1","key":"824_CR49","first-page":"68","volume":"36","author":"T Sun","year":"2008","unstructured":"Sun T, et al. [Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. Zhonghua xin xue guan bing za zhi. 2008;36(1):68\u201371.","journal-title":"Zhonghua xin xue guan bing za zhi"},{"issue":"5","key":"824_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3892\/etm.2020.9245","volume":"20","author":"M Zong","year":"2020","unstructured":"Zong M, et al. Irbesartan ameliorates myocardial fibrosis in diabetic cardiomyopathy rats by inhibiting the TGF\u03b21\/Smad2\/3 pathway. Exp Ther Med. 2020;20(5):117.","journal-title":"Exp Ther Med"},{"issue":"1","key":"824_CR51","first-page":"18","volume":"1","author":"M Tian","year":"2015","unstructured":"Tian M, et al. Tumor necrosis factor-\u03b1 and its role as a mediator in myocardial infarction: A brief review. Chronic Dis Transl Med. 2015;1(1):18\u201326.","journal-title":"Chronic Dis Transl Med"},{"issue":"11","key":"824_CR52","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1161\/01.CIR.99.11.1492","volume":"99","author":"MW Irwin","year":"1999","unstructured":"Irwin MW, et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation. 1999;99(11):1492\u20138.","journal-title":"Circulation"},{"key":"824_CR53","first-page":"100366","volume":"23","author":"AH Mahmoud","year":"2019","unstructured":"Mahmoud AH, et al. PTEN gene & TNF-alpha in acute myocardial infarction. Int J Cardiol Heart Vasc. 2019;23:100366.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"6","key":"824_CR54","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1139\/cjpp-2015-0356","volume":"94","author":"MdlL Ibarra-Lara","year":"2016","unstructured":"Ibarra-Lara MdlL, et al. Peroxisome proliferator-activated receptors (PPAR) downregulate the expression of pro-inflammatory molecules in an experimental model of myocardial infarction. Can J Physiol Pharmacol. 2016;94(6):634\u201342.","journal-title":"Can J Physiol Pharmacol"},{"issue":"2","key":"824_CR55","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.intimp.2015.02.029","volume":"25","author":"H Durairaj","year":"2015","unstructured":"Durairaj H, Steury MD, Parameswaran N. Paroxetine differentially modulates LPS-induced TNF\u03b1 and IL-6 production in mouse macrophages. Int Immunopharmacol. 2015;25(2):485\u201392.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"824_CR56","doi-asserted-by":"publisher","first-page":"e22464","DOI":"10.1002\/jbt.22464","volume":"34","author":"M Kabiri","year":"2020","unstructured":"Kabiri M, et al. Paroxetine modulates immune responses by activating a JAK2\/STAT3 signaling pathway. J Biochem Mol Toxicol. 2020;34(5):e22464.","journal-title":"J Biochem Mol Toxicol"},{"issue":"4","key":"824_CR57","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10557-005-3695-6","volume":"19","author":"C Berthonneche","year":"2005","unstructured":"Berthonneche C, et al. AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats. Cardiovasc Drugs Ther. 2005;19(4):251\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"824_CR58","doi-asserted-by":"publisher","first-page":"e0202297","DOI":"10.1371\/journal.pone.0202297","volume":"13","author":"M Boccellino","year":"2018","unstructured":"Boccellino M, et al. AT1-receptor blockade: Protective effects of irbesartan in cardiomyocytes under hypoxic stress. PLoS ONE. 2018;13(10):e0202297.","journal-title":"PLoS ONE"},{"issue":"1","key":"824_CR59","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41398-019-0521-7","volume":"9","author":"L Carboni","year":"2019","unstructured":"Carboni L, et al. Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies. Transl Psychiatry. 2019;9(1):182.","journal-title":"Transl Psychiatry"},{"issue":"5","key":"824_CR60","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cardfail.2007.02.004","volume":"13","author":"Y Nagatomo","year":"2007","unstructured":"Nagatomo Y, et al. Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure. J Card Fail. 2007;13(5):365\u201371.","journal-title":"J Card Fail"},{"key":"824_CR61","doi-asserted-by":"publisher","first-page":"738325","DOI":"10.3389\/fcvm.2021.738325","volume":"8","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, et al. The Role of the VEGF Family in Coronary Heart Disease. Front Cardiovasc Med. 2021;8:738325.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"824_CR62","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2967\/jnumed.107.040576","volume":"49","author":"M Rodriguez-Porcel","year":"2008","unstructured":"Rodriguez-Porcel M, et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med. 2008;49(4):667\u201373.","journal-title":"J Nucl Med"},{"issue":"2","key":"824_CR63","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.mvr.2010.03.014","volume":"80","author":"T Zhao","year":"2010","unstructured":"Zhao T, et al. Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction. Microvasc Res. 2010;80(2):188\u201394.","journal-title":"Microvasc Res"},{"issue":"3","key":"824_CR64","first-page":"533","volume":"34","author":"R Yoshimura","year":"2022","unstructured":"Yoshimura R, Okamoto N, Ikenouchi A. Effects of Paroxetine on Plasma Levels of Vascular Endothelial Growth Factor in Patients with Major Depression. Psychiatr Danub. 2022;34(3):533\u20134.","journal-title":"Psychiatr Danub"},{"issue":"3","key":"824_CR65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1388-9842(01)00129-5","volume":"3","author":"RA de Boer","year":"2001","unstructured":"de Boer RA, et al. Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur J Heart Fail. 2001;3(3):331\u20133.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"824_CR66","first-page":"2518","volume":"13","author":"Y Fan","year":"2021","unstructured":"Fan Y, et al. Effects of metoprolol on serum inflammatory factors and myocardial ischemia in rats modeled with coronary heart disease. Am J Transl Res. 2021;13(4):2518\u201327.","journal-title":"Am J Transl Res"},{"issue":"11","key":"824_CR67","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.repc.2023.03.018","volume":"42","author":"MY Tepeba\u015fi","year":"2023","unstructured":"Tepeba\u015fi MY, et al. Irbesartan has a curative effect on lipopolysaccharide-induced cardiotoxicity by antioxidant and antiapoptotic pathways. Rev Port Cardiol. 2023;42(11):895\u2013903.","journal-title":"Rev Port Cardiol"},{"issue":"6","key":"824_CR68","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1006\/jmcc.1998.0686","volume":"30","author":"NG Vejlstrup","year":"1998","unstructured":"Vejlstrup NG, et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol. 1998;30(6):1215\u201323.","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"824_CR69","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/01.RES.87.3.241","volume":"87","author":"P Ferdinandy","year":"2000","unstructured":"Ferdinandy P, et al. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res. 2000;87(3):241\u20137.","journal-title":"Circ Res"},{"issue":"6","key":"824_CR70","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1161\/hc3201.092284","volume":"104","author":"Q Feng","year":"2001","unstructured":"Feng Q, et al. Increased Inducible Nitric Oxide Synthase Expression Contributes to Myocardial Dysfunction and Higher Mortality After Myocardial Infarction in Mice. Circulation. 2001;104(6):700\u20134.","journal-title":"Circulation"},{"key":"824_CR71","doi-asserted-by":"publisher","first-page":"p9154295","DOI":"10.1155\/2022\/9154295","volume":"2022","author":"P Panda","year":"2022","unstructured":"Panda P, et al. Biomarkers of Oxidative Stress Tethered to Cardiovascular Diseases. Oxid Med Cell Longev. 2022;2022:p9154295.","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"824_CR72","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s13105-016-0494-4","volume":"72","author":"AM Abbas","year":"2016","unstructured":"Abbas AM. Cardioprotective effect of resveratrol analogue isorhapontigenin versus omega-3 fatty acids in isoproterenol-induced myocardial infarction in rats. J Physiol Biochem. 2016;72(3):469\u201384.","journal-title":"J Physiol Biochem"},{"issue":"3","key":"824_CR73","doi-asserted-by":"publisher","first-page":"286","DOI":"10.5937\/jomb0-28879","volume":"40","author":"N Alada\u011f","year":"2021","unstructured":"Alada\u011f N, et al. Oxidants and antioxidants in myocardial infarction (MI): Investigation of ischemia modified albumin, malondialdehyde, superoxide dismutase and catalase in individuals diagnosed with ST elevated myocardial infarction (STEMI) and non-STEMI (NSTEMI). J Med Biochem. 2021;40(3):286\u201394.","journal-title":"J Med Biochem"},{"issue":"3","key":"824_CR74","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00395-017-0614-5","volume":"112","author":"TR Lassen","year":"2017","unstructured":"Lassen TR, et al. Effect of paroxetine on left ventricular remodeling in an in vivo rat model of myocardial infarction. Basic Res Cardiol. 2017;112(3):26.","journal-title":"Basic Res Cardiol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00824-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T12:12:51Z","timestamp":1734523971000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00824-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00824-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"20 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study protocol was reviewed and approved by the Ethics Committee of King Saud University (Reference: KSU-SE-23-41, issued on 16th May 2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable, as the current study did not involve humans.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}